News | December 16, 2021
Syngene extends contract with Amgen till 2026
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Subscribe To Our Newsletter & Stay Updated
